Trv Gp Iv LLC Invests $133.50 Billion in Maze Therapeutics, Inc. $MAZE

Key Points

• Trv Gp Iv LLC acquired 4.47 million Maze Therapeutics shares in the second quarter, representing an approximately 8.08% stake and 52.6% of its portfolio. The filing valued the position at about $133.5 billion, a figure that appears unusually large relative to Maze’s reported $1.62 billion market capitalization.
• Analyst sentiment remains broadly positive: Maze has an average “Buy” rating and a consensus price target of $66, although some firms maintain “Sell” ratings. BTIG reiterated its Buy rating with a $46 target.
• Company insiders sold 140,674 shares worth approximately $3.9 million over the past 90 days, including sales by the CEO and CMO under pre-arranged Rule 10b5-1 plans. Maze reported quarterly EPS of -$0.76, matching estimates, while its shares opened at $29.13.

Trv Gp Iv LLC purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,473,958 shares of the company's stock, valued at approximately $133,502,907,000. Maze Therapeutics accounts for 52.6% of Trv Gp Iv LLC's investment portfolio, making the stock its largest position. Trv Gp Iv LLC owned approximately 8.08% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after buying an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after buying an additional 738 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock worth $55,000 after acquiring an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock worth $247,000 after acquiring an additional 931 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock worth $135,000 after acquiring an additional 977 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have commented on MAZE shares. Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. BTIG Research reiterated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maze Therapeutics currently has an average rating of "Buy" and an average target price of $66.00.

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares of the company's stock, valued at $445,680.62. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares of the company's stock, valued at $699,643.26. This represents a 59.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 140,674 shares of company stock worth $3,904,707. Insiders own 5.30% of the company's stock.

Maze Therapeutics Trading Up 4.2%

Shares of Maze Therapeutics stock opened at $29.13 on Wednesday. The firm's 50 day moving average is $27.98 and its 200 day moving average is $32.73. The firm has a market capitalization of $1.62 billion, a PE ratio of -11.56 and a beta of 2.22. Maze Therapeutics, Inc. has a 1 year low of $12.81 and a 1 year high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). Equities research analysts forecast that Maze Therapeutics, Inc. will post -2.71 earnings per share for the current fiscal year.

Maze Therapeutics Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source